133808-94-3

Upstream product

• 153471-17-1 (4R,5R,6S)-6-[(R)-1-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-3-(diphenoxy-phosphoryloxy)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid allyl ester 
• 158299-15-1 3-<(2R)-2-<(2R,3S)-3-<(1R)-1-(tert-Butyldimethylsiloxy)ethyl>-4-oxoazetidin-2-yl>propionyl>spiro-<2,3-dihydro-4H-1,3-benzoxazine-2,1'-cyclohexan>-4-one 
• 76899-07-5 (3R,4R)-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]-4-acetoxyazetidin-2-one 
• 117893-97-7 allyl (4R,5R,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-3,7-dioxo-1-azabicyclo-[3.2.0]heptane-2-carboxylate 
• 2524-64-3 chlorophosphoric acid diphenyl ester 

Downstream Products

• 304655-63-8 allyl (1R,5S,6S)-2-[(3S,5R)-1-allyloxycarbonyl-5-[4-(N-allyloxycarbonylaminomethyl)phenyl]pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate 
• 228267-15-0 allyl (1R,5S,6S)-2-[(3S,5R)-1-allyloxycarbonyl-5-[4-(N-methyl-N-alylloxycarbonylaminomethyl)phenyl]pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate 
• 288400-01-1 (4R,5S,6S)-3-[(3S,5S)-1-Allyloxycarbonyl-5-(1-phenyl-1H-tetrazol-5-ylsulfanylmethyl)-pyrrolidin-3-ylsulfanyl]-6-((R)-1-hydroxy-ethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid allyl ester 
• 312297-55-5 allyl (1R,5S,6S)-2-[(3S,5R)-1-allyloxycarbonyl-5-[4-[(S)-1-allyloxycarbonylamino-2-carbamoylethyl]phenyl]pyrrolidin-3-ylthio]-6-[(R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate 

Relevant academic research and scientific papers

A carbapenem antibiotic nucleus MPP synthesis method

The invention discloses a synthesis method of carbapenem mother nucleus MPP. Compared with the prior art, the synthesis method disclosed by the invention has the advantages that a synthesis route of MPP is redesigned, the synthesis efficiency is improved, reaction raw materials are relatively low in price, reaction conditions are not strict, the energy consumption and cost are relatively reduced, and meanwhile, the yield is increased to more than 62%.

CARBAPENEM COMPOUND

The present invention relates to a carbapenem compound represented by formula (Ia) shown below: The carbapenem compound preferably has a crystalline form, and more preferably, the crystalline form has a powder X-ray diffraction pattern with peaks at 15.64, 9.93, 6.83, 6.52, 5.44, 5.01, 4.72, 4.50, 4.33, 4.24, 3.98, 3.85, 3.57, 3.41, 3.31, 3.10 2.76, and 2.67 as d-spacings (?).